Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
about
Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunityHIV and aging: emerging research issuesPediatric Statin Administration: Navigating a Frontier with Limited DataImmune activation and HIV persistence: considerations for novel therapeutic interventions.Chronic HIV disease and activation of the coagulation systemRosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.Preventing Heart Failure in Inflammatory and Immune DisordersImmune activation and cardiovascular disease in chronic HIV infection.Inflammation, immune activation, and cardiovascular disease in HIV.Cardiovascular disease and HIV infection.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionEvidence-based review of statin use in patients with HIV on antiretroviral therapy.Integrating HIV and hypertension management in low-resource settings: Lessons from Malawi.Increased Systemic Inflammation and Gut Permeability Among Women With Treated HIV Infection in Rural Uganda
P2860
Q26773267-C20E486A-E050-4651-8371-3AF0A8EE7487Q27016011-BA7347A3-489F-4C8D-8CC3-412BDA0F5029Q28068014-B6D912CB-C777-48F4-A507-80DC05080E95Q33698781-E2C418F9-CB70-48DA-BDCE-95D06B887288Q34342368-381624E0-1796-46A3-87F6-2978A8D512CCQ34736818-55314624-BB85-41A4-9368-D9AC64DE8497Q35994802-532D5E1E-4AC8-4D9A-ABFE-3683F9F88182Q36556082-C5D74D4F-F570-46FD-ABD3-FA709922946BQ36957752-081E356F-F6A7-477D-8086-C681A3166645Q37661603-0EF7C93E-B387-42C0-A4CC-2E9E39E70062Q38177684-18278349-66D6-44F3-A7ED-937BC4617199Q38749963-002A3CFF-87F2-4787-A634-BA3A67A1ABFEQ42656331-EB575FE5-E38D-43E4-B568-4E2A07BA02F0Q55016986-11F341FC-9A52-439A-BF3B-F68B40243423Q56334211-C03003DC-6D4A-47AE-AC88-3C2097E6348B
P2860
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Angiotensin converting enzyme ...... a feasibility randomized trial
@ast
Angiotensin converting enzyme ...... a feasibility randomized trial
@en
Angiotensin converting enzyme ...... a feasibility randomized trial
@nl
type
label
Angiotensin converting enzyme ...... a feasibility randomized trial
@ast
Angiotensin converting enzyme ...... a feasibility randomized trial
@en
Angiotensin converting enzyme ...... a feasibility randomized trial
@nl
prefLabel
Angiotensin converting enzyme ...... a feasibility randomized trial
@ast
Angiotensin converting enzyme ...... a feasibility randomized trial
@en
Angiotensin converting enzyme ...... a feasibility randomized trial
@nl
P2093
P2860
P1433
P1476
Angiotensin converting enzyme ...... a feasibility randomized trial
@en
P2093
Daniel Duprez
Frank Rhame
James D Neaton
Jason V Baker
Kathleen Huppler Hullsiek
Keith Henry
Rachel Prosser
Richard Grimm
Russell P Tracy
P2860
P304
P356
10.1371/JOURNAL.PONE.0046894
P407
P577
2012-01-01T00:00:00Z